These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 8700879)

  • 1. Long-term in vitro correction of alpha-L-iduronidase deficiency (Hurler syndrome) in human bone marrow.
    Fairbairn LJ; Lashford LS; Spooncer E; McDermott RH; Lebens G; Arrand JE; Arrand JR; Bellantuono I; Holt R; Hatton CE; Cooper A; Besley GT; Wraith JE; Anson DS; Hopwood JJ; Dexter TM
    Proc Natl Acad Sci U S A; 1996 Mar; 93(5):2025-30. PubMed ID: 8700879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Towards gene therapy of Hurler syndrome.
    Fairbairn LJ; Lashford LS; Spooncer E; McDermott RH; Lebens G; Arrand JE; Arrand JR; Bellantuono I; Holt R; Hatton CE; Cooper A; Besley GT; Wraith JE; Anson DS; Hopwood JJ; Dexter TM
    Cas Lek Cesk; 1997 Jan; 136(1):27-31. PubMed ID: 9127508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrovirus-mediated transfer of the human alpha-L-iduronidase cDNA into human hematopoietic progenitor cells leads to correction in trans of Hurler fibroblasts.
    Huang MM; Wong A; Yu X; Kakkis E; Kohn DB
    Gene Ther; 1997 Nov; 4(11):1150-9. PubMed ID: 9425437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene therapy for canine alpha-L-iduronidase deficiency: in utero adoptive transfer of genetically corrected hematopoietic progenitors results in engraftment but not amelioration of disease.
    Lutzko C; Omori F; Abrams-Ogg AC; Shull R; Li L; Lau K; Ruedy C; Nanji S; Gartley C; Dobson H; Foster R; Kruth S; Dubé ID
    Hum Gene Ther; 1999 Jun; 10(9):1521-32. PubMed ID: 10395377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetically corrected autologous stem cells engraft, but host immune responses limit their utility in canine alpha-L-iduronidase deficiency.
    Lutzko C; Kruth S; Abrams-Ogg AC; Lau K; Li L; Clark BR; Ruedy C; Nanji S; Foster R; Kohn D; Shull R; Dubé ID
    Blood; 1999 Mar; 93(6):1895-905. PubMed ID: 10068662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of the mouse model of mucopolysaccharidosis I with retrovirally transduced bone marrow.
    Zheng Y; Rozengurt N; Ryazantsev S; Kohn DB; Satake N; Neufeld EF
    Mol Genet Metab; 2003 Aug; 79(4):233-44. PubMed ID: 12948739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In utero injection of alpha-L-iduronidase-carrying retrovirus in canine mucopolysaccharidosis type I: infection of multiple tissues and neonatal gene expression.
    Meertens L; Zhao Y; Rosic-Kablar S; Li L; Chan K; Dobson H; Gartley C; Lutzko C; Hopwood J; Kohn D; Kruth S; Hough MR; Dubé ID
    Hum Gene Ther; 2002 Oct; 13(15):1809-20. PubMed ID: 12396614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical Testing of the Safety and Tolerability of Lentiviral Vector-Mediated Above-Normal Alpha-L-Iduronidase Expression in Murine and Human Hematopoietic Cells Using Toxicology and Biodistribution Good Laboratory Practice Studies.
    Visigalli I; Delai S; Ferro F; Cecere F; Vezzoli M; Sanvito F; Chanut F; Benedicenti F; Spinozzi G; Wynn R; Calabria A; Naldini L; Montini E; Cristofori P; Biffi A
    Hum Gene Ther; 2016 Oct; 27(10):813-829. PubMed ID: 27431943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retroviral-mediated transfer of the human glucocerebrosidase gene into cultured Gaucher bone marrow.
    Nolta JA; Yu XJ; Bahner I; Kohn DB
    J Clin Invest; 1992 Aug; 90(2):342-8. PubMed ID: 1379609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mobilization and transduction of peripheral blood progenitor cells in patients with mucopolysaccharidosis I.
    Hubel A; Stroncek D; Pan D; Whitley CB; McCullough J
    J Hematother; 1998 Dec; 7(6):505-14. PubMed ID: 9919944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hematopoietic Stem- and Progenitor-Cell Gene Therapy for Hurler Syndrome.
    Gentner B; Tucci F; Galimberti S; Fumagalli F; De Pellegrin M; Silvani P; Camesasca C; Pontesilli S; Darin S; Ciotti F; Sarzana M; Consiglieri G; Filisetti C; Forni G; Passerini L; Tomasoni D; Cesana D; Calabria A; Spinozzi G; Cicalese MP; Calbi V; Migliavacca M; Barzaghi F; Ferrua F; Gallo V; Miglietta S; Zonari E; Cheruku PS; Forni C; Facchini M; Corti A; Gabaldo M; Zancan S; Gasperini S; Rovelli A; Boelens JJ; Jones SA; Wynn R; Baldoli C; Montini E; Gregori S; Ciceri F; Valsecchi MG; la Marca G; Parini R; Naldini L; Aiuti A; Bernardo ME;
    N Engl J Med; 2021 Nov; 385(21):1929-1940. PubMed ID: 34788506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myoblast gene therapy in canine mucopolysaccharidosis. I: Abrogation by an immune response to alpha-L-iduronidase.
    Shull RM; Lu X; McEntee MF; Bright RM; Pepper KA; Kohn DB
    Hum Gene Ther; 1996 Aug; 7(13):1595-603. PubMed ID: 8864760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reprogramming erythroid cells for lysosomal enzyme production leads to visceral and CNS cross-correction in mice with Hurler syndrome.
    Wang D; Zhang W; Kalfa TA; Grabowski G; Davies S; Malik P; Pan D
    Proc Natl Acad Sci U S A; 2009 Nov; 106(47):19958-63. PubMed ID: 19903883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene therapy augments the efficacy of hematopoietic cell transplantation and fully corrects mucopolysaccharidosis type I phenotype in the mouse model.
    Visigalli I; Delai S; Politi LS; Di Domenico C; Cerri F; Mrak E; D'Isa R; Ungaro D; Stok M; Sanvito F; Mariani E; Staszewsky L; Godi C; Russo I; Cecere F; Del Carro U; Rubinacci A; Brambilla R; Quattrini A; Di Natale P; Ponder K; Naldini L; Biffi A
    Blood; 2010 Dec; 116(24):5130-9. PubMed ID: 20847202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retroviral vector design studies toward hematopoietic stem cell gene therapy for mucopolysaccharidosis type I.
    Pan D; Aronovich E; McIvor RS; Whitley CB
    Gene Ther; 2000 Nov; 7(21):1875-83. PubMed ID: 11110421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Marrow stromal cells from patients affected by MPS I differentially support haematopoietic progenitor cell development.
    Baxter MA; Wynn RF; Schyma L; Holmes DK; Wraith JE; Fairbairn LJ; Bellantuono I
    J Inherit Metab Dis; 2005; 28(6):1045-53. PubMed ID: 16435198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Normalization and improvement of CNS deficits in mice with Hurler syndrome after long-term peripheral delivery of BBB-targeted iduronidase.
    El-Amouri SS; Dai M; Han JF; Brady RO; Pan D
    Mol Ther; 2014 Dec; 22(12):2028-2037. PubMed ID: 25088464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome of second hematopoietic cell transplantation in Hurler syndrome.
    Grewal SS; Krivit W; Defor TE; Shapiro EG; Orchard PJ; Abel SL; Lockman LA; Ziegler RS; Dusenbery KE; Peters C
    Bone Marrow Transplant; 2002 Mar; 29(6):491-6. PubMed ID: 11960268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arylsulfatase B activities and glycosaminoglycan levels in retrovirally transduced mucopolysaccharidosis type VI cells. Prospects for gene therapy.
    Fillat C; Simonaro CM; Yeyati PL; Abkowitz JL; Haskins ME; Schuchman EH
    J Clin Invest; 1996 Jul; 98(2):497-502. PubMed ID: 8755662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mixed donor chimerism and low level iduronidase expression may be adequate for neurodevelopmental protection in Hurler Syndrome.
    Conway J; Dyack S; Crooks BN; Fernandez CV
    J Pediatr; 2005 Jul; 147(1):106-8. PubMed ID: 16027706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.